WO2010079978A2 - Abh 항원을 이용한 염증질환 개선용 조성물 - Google Patents
Abh 항원을 이용한 염증질환 개선용 조성물 Download PDFInfo
- Publication number
- WO2010079978A2 WO2010079978A2 PCT/KR2010/000103 KR2010000103W WO2010079978A2 WO 2010079978 A2 WO2010079978 A2 WO 2010079978A2 KR 2010000103 W KR2010000103 W KR 2010000103W WO 2010079978 A2 WO2010079978 A2 WO 2010079978A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- antigen
- expression
- abh
- skin
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01041—Polypeptide N-acetylgalactosaminyltransferase (2.4.1.41)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Definitions
- the present invention relates to a composition for improving an inflammatory disease, and more particularly, an inflammatory disease in an epithelial cell including skin capable of preventing or treating inflammatory reactions and barrier functions and anti-aging, skin elasticity, and aging. It relates to a composition for improvement.
- the ABH antigen is an antigen that determines the ABO blood group, and the ABO blood group is determined by the difference in activity of the ABO gene at the glycosylated terminus of a specific structure. Since the ABH antigen is expressed in a large amount on the surface of red blood cells, the blood type acts as a major cause of rejection when transfused with other blood. ABH antigen is known to be expressed in a wide variety of tissues such as blood vessels, salivary glands, sweat glands, small intestine, large intestine, and pancreas in addition to erythrocytes. Expression in the polar and basal layers (Ravn et al.
- the ABH antigen becomes A antigen (type A) when N-acetylgalactosamine binds to the end of fucose-galactose at the end of the glycosylation terminal of a protein or lipid.
- B type when two kinds coexist, it becomes AB type, and when nothing is combined, it becomes H antigen (type O) (see Fig. 1).
- FUT1 or FUT2 fucosyl transferase 1 or 2
- the present invention provides a composition for improving inflammatory disease containing an ABH antigen or a substance for controlling the expression of the ABH antigen as an active ingredient.
- the inflammatory disease may include, but is not limited to, inflammatory skin diseases and inflammatory diseases of tissues such as the stomach, esophagus, small intestine, urethra, conjunctiva, without limitation.
- the composition of the present invention is preferably in the form of a pharmaceutical composition or cosmetic composition, but is not necessarily limited thereto.
- the "ABH antigen” is used to mean not only ABH antigens but also analogs of ABH antigens and conjugates of ABH antigens and ABH antigen analogs.
- the "ABH antigen analogue” is a substance containing a sugar structure that is reactive with an ABH antibody, or a substance having a similar structure and capable of simulating or inhibiting the physiological function of the ABH antigen, or a specific carrier for such an analogue. It includes the case where the conjugate is fixed to the molecule to make and add a conjugate.
- an ABH antigen analog refers to a substance in which one or more other compounds, such as monosaccharides, amino acids, and the like, are further bound to the ABH antigen, and have a function that is identical to that of the ABH antigen.
- a substance regulating the expression of the ABH antigen is used as a meaning including all substances that increase or decrease the expression of the ABH antigen.
- Substances that increase the expression of the ABH antigen include biosynthesis of the ABH antigen, such as increased expression or activity of the stepwise glycosylation enzymes of the ABH antigen, including ABO, FUT1, FUT2, etc., proteins, lipids, and sugars to which the ABH antigen is bound. Any substance that increases the biosynthesis of the ABH antigen by increasing the expression of, etc. may be included regardless of its type.
- Substances that increase the biosynthesis of the ABH antigen may be a gene encoding the stepwise glycosylating enzymes for synthesizing the ABH antigen including ABO, FUT1, FUT2 and the like, or a vector including the gene.
- the expression of the ABH antigen is increased to normalize the differentiation of the skin, thereby enhancing immunity, balancing the immune system, and enhancing skin barrier function, thereby making healthy skin.
- the vector may be produced by any of the methods well known in the art, or may be readily purchased on the market.
- the substance for increasing the expression of the ABH antigen may be willow extract or golden extract (see FIG. 6B).
- agents that reduce the expression of ABH antigens include biosynthesis of ABH antigens, such as reduced or reduced activity of glycosylation enzymes in stages of ABH antigens including ABO, FUT1, FUT2, etc., proteins to which ABH antigens are bound, Any substance that reduces the biosynthesis of the ABH antigen by reducing the expression of lipids, sugars, etc. may be included regardless of its type.
- Substances that reduce the biosynthesis of the ABH antigen may be siRNAs or shRNAs that inhibit the expression of glycosylation enzymes that synthesize ABH antigens including ABO, FUT1, FUT2, etc., or vectors containing siRNAs, shRNAs, or antisense coding sequences. have.
- the expression of the ABH antigen is reduced to suppress the Th1 inflammatory response and to alleviate the symptoms of the inflammatory disease by temporarily calming the excessive inflammatory response.
- the vector may be produced by any of the methods well known in the art, or may be readily purchased on the market.
- the substance for reducing the expression of the ABH antigen may be prickly pear extract, thistle extract, shiitake mushroom extract, ginseng extract or echinacea extract (see FIG. 6A).
- the ABH antigen or a substance regulating the expression of the ABH antigen is preferably contained in an amount of 0.001 to 10% by weight in the total composition. If it is less than 0.001% by weight, the effect of improving inflammatory diseases is insignificant, and if it is more than 10% by weight, compatibility with other components and formulation stability are poor. From this point of view, the ABH antigen or the substance regulating the expression of the ABH antigen more preferably contains 0.01 to 5% by weight.
- Inflammatory diseases applicable to the present invention may include, without limitation, inflammatory skin diseases and inflammatory diseases of tissues such as stomach, esophagus, small intestine, urethra, conjunctiva and the like.
- the skin diseases include diseases such as psoriasis, atopic dermatitis, mammary glands, cataracts, acne, lupus erythematosus, skin aging and skin wrinkles, but are not necessarily limited thereto, and may be caused by inflammatory reactions in the skin. Any disease can be included within the scope of the skin disease of the present invention.
- the formulation of the composition of the present invention is not particularly limited, but is preferably a formulation of an external preparation for skin, and a preferred form of the external preparation for external preparation includes softening cream, nourishing cosmetic, massage cream, nourishing cream, pack, gel or skin adhesion.
- Cosmetic compositions having formulations of type cosmetics, and other preferred forms include formulations of transdermal dosage forms such as lotions, ointments, gels, creams, patches or sprays.
- other components than the essential components described above can be appropriately selected and blended by those skilled in the art without difficulty according to the formulation or purpose of use of other external preparations.
- composition of the present invention When the composition of the present invention is applied to a cosmetic, it preferably contains a cosmetically acceptable medium or base.
- a cosmetically acceptable medium or base These are all formulations suitable for topical application, for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, aqueous phase, and / or It may be provided in the form of a nonionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
- the cosmetic composition of the present invention may be prepared in the form of topically or systemically applicable auxiliaries commonly used in the field of dermatology by containing a dermatologically acceptable medium or base, and these compositions are conventionally used in the art. It may be prepared according to the method.
- the cosmetic composition is a fatty substance, an organic solvent, a dissolving agent, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ion Any commonly used in type or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics It may contain adjuvants conventionally used in the cosmetic field, such as other ingredients. These adjuvants are introduced in amounts generally used in the cosmetic field.
- the composition of the present invention When the composition of the present invention is applied to a pharmaceutical product, the composition of the present invention contains an ABH antigen or a substance that controls the expression of the ABH antigen as an active ingredient, and can be administered orally or parenterally during clinical administration, and general pharmaceutical preparations. It can be used in the form of. That is, the composition for improving inflammatory diseases of the present invention may be administered in various oral and parenteral formulations during actual clinical administration, and when formulated, fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are commonly used It is prepared using diluent or excipient.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, carbonic acid, or the like that control the expression of the ABH antigen or the ABH antigen.
- excipients such as starch, carbonic acid, or the like that control the expression of the ABH antigen or the ABH antigen.
- lubricants such as magnesium styrate talc are also used.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories.
- the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
- a suppository base witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, and the like may be used, but are not limited thereto.
- the active ingredient can be easily formulated according to the conventional method, and at this time, surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents, and other commonly used auxiliaries can be suitably used.
- the dose of the ABH antigen, which is an active ingredient of the composition of the present invention, or a substance that modulates the expression of the ABH antigen is determined by the age, sex, and weight of the subject in need of improvement of the inflammatory disease, and the specific disease or pathological condition, disease or pathology to be treated. Severity, route of administration and judgment of prescriber. Dosage determination based on these factors is within the level of those skilled in the art and can be applied at the level of the person skilled in the art by external application to the topical site for preparations other than injections, and in the case of injections topically injection into the dermis and subcutaneous fat However, the present invention is not limited thereto.
- dosages range from approximately 0.001 mg / kg / day to 2,000 mg / kg / day. More preferred dosages are 1 ⁇ g / kg / day to 100 ⁇ g / kg / day. Dosage units may, for example, contain 1, 2, 3 or 4 times the individual dose, or 1/2, 1/3 or 1/4 times. Individual dosages contain amounts in which the active ingredient is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
- inflammatory skin diseases such as psoriasis, atopy, young glands, pemphigus, accompanied by abnormal inflammatory response to the skin, imbalance of immune system and differentiation of abnormal keratinocytes due to various genetic and environmental factors
- abnormal expression such as abnormal expression of ABH antigen was observed at abnormal positions according to loss of expression of ABH antigen in granule layer or abnormal differentiation of keratinocyte layer (see FIGS. 4 and 5). Differentiation of keratinocytes into an incomplete granular layer in these various skin diseases may be a major cause of problems in skin barrier function.
- the expression of ABH antigen in the granule layer was found to be largely lost after 3 days (see FIG. 3).
- atopic dermatitis which is thought to be an imbalance of cytokines that regulate the inflammatory response, followed by a lowering stage of the Th1 inflammatory response, the cause of which is unknown, and whose exact antigen is unclear.
- Th2 immune response accompanied by an increase in immunoglobulin E (IgE) levels
- IgE immunoglobulin E
- a decrease in the expression of ABH antigens in the granular layer by various causes may serve as one of the causes of the decrease in the initial Th1 inflammatory response.
- the improvement may help prevent and treat skin diseases such as atopic dermatitis.
- the loss of ABH antigens in various inflammatory skin diseases causes abnormal inflammatory reactions, resulting in adverse effects of normal skin differentiation and inherent defense mechanisms of the skin.
- Adding a useful substance to increase the expression of can boost the normal immune response.
- increasing the expression of ABH antigens in the granular layer complements the decreased expression of transient or genetic ABH antigens by enhancing the immune response in the skin, thereby assisting in maintaining a normal skin immune system, leading to abnormal skin immune system
- Various skin diseases caused by imbalance can be treated and prevented, and the skin barrier function is strengthened to help maintain healthy skin.
- the present invention also includes screening for substances that promote or differentiate the keratinocytes of the epidermis from candidates to increase or decrease the expression of ABH antigens in vitro or in vivo.
- useful substances can be selected by treating the cells in equal amounts under the same conditions, then culturing the cells, and measuring the amount of the ABH antigen using a Western blot method.
- any of the methods known in the art for screening useful proteins from candidates is applicable.
- the present invention provides a skin cosmetic method comprising enhancing the endogenous immune response by increasing the expression level of the normal ABH antigen in the granule layer of normal skin and damaged skin, improving skin barrier function and promoting the expression of antimicrobial peptides. .
- the present invention temporarily reduces the expression level of the ABH antigen in the skin in which the inflammatory response occurs continuously, thereby attenuating the expression of factors related to the Th1 inflammatory response, thereby alleviating the symptoms of skin diseases caused by an excessive inflammatory response.
- the present invention is to increase the amount of normal ABH antigen expression in the granule layer in normalized immune response in the skin with weakened immune function, thereby suppressing abnormal inflammatory response and incomplete differentiation of keratinocytes. It provides a way to restore function.
- the composition of the present invention has the effect of improving or assisting the symptoms of inflammatory diseases involving inflammatory reactions in various tissues, including the skin, and damaged by maintaining healthy skin and promoting the expression of antimicrobial peptides by improving skin barrier function May help recover weak skin.
- it has the effect of preventing or improving aging, strengthening skin elasticity, preventing or improving skin wrinkles by continuously inhibiting inflammatory reactions, and is useful for screening useful substances that can improve inflammatory skin diseases and aging. Can be.
- 1 is a schematic showing the chemical structure of blood type sugars.
- Figure 2 is a photograph showing the expression of ABH antigen in normal tissues.
- Figure 3 is a photograph showing the expression reduction of ABH antigen (type B antigen) in the skin by ultraviolet irradiation.
- Figure 4 is a photograph showing the expression of ABH antigen in various skin disease tissue.
- Figure 5 shows the immunohistochemical staining results of various skin diseases.
- Figure 6 is an electrophoresis picture showing the effect of various natural product extracts on the expression of ABH antigen.
- Figure 7 is an electrophoretic picture showing the effect of the treatment of ABH antigen on the expression of blood type antigen.
- Figure 8 is an immunohistochemical staining picture showing the effect of the administration of monosaccharides constituting the ABH antigen on the expression of blood type antigen.
- Figure 9 is an electrophoresis picture showing the effect of the administration of the monosaccharides constituting the ABH antigen on the expression of blood type antigen.
- FIG. 10 is a Western blot photograph showing reduced expression of ICAM-1, HLA-DR by ABH antigen ablation.
- 11 is a graph of real-time PCR results showing reduced expression of IL-8, GM-CSF by ABH antigen removal.
- FIG. 13 is a graph showing whether the inhibition of BD-2 expression by TNF- ⁇ or IL-1 ⁇ treatment after ABH antigen removal.
- the antibody that specifically binds to the ABH antigen was used to examine the expression of the ABH antigen in each tissue by immunohistochemical staining. Specifically, the biopsy tissue was placed in 10% formalin and fixed overnight, and then formalin was removed and the tissue was dehydrated to solidify in paraffin to make blocks. Thereafter, the tissue was cut to a thickness of 4 ⁇ m and attached to a slide to dissolve paraffin for 1 hour at 58 ° C. in a dry oven.
- Treated with xylene 4 times for 5 minutes to completely remove paraffin re-hydrate the tissue in stages by soaking twice in 100% ethanol for 1 minute, 95% ethanol for 1 minute, 80% ethanol, 70% ethanol for 1 minute After washing, the mixture was washed with running tap water for 5 minutes, washed again with distilled water for 5 minutes, and then autoclaved at 120 ° C. for 10 minutes in a pH 6.0 TRS (Dako). After cooling the tissue for 10 minutes in a bath, it was washed twice with distilled water for 5 minutes, and then washed for 5 minutes with PBS, and soaked in 3% hydrogen peroxide solution diluted with PBS for 10 minutes.
- the tissues were washed three times for 10 minutes in PBS, and then bordered with a PAP pen around the tissues, and treated with the blocking solution (Zymed) for 30 minutes.
- a primary antibody that recognizes a type A or B antigen
- HRP secondary antibody
- HRP horseradish peroxidase
- the ABH antigen is not only red blood cells but also the individual's blood type, such as gastrointestinal (type A), esophagus (type A), small intestine (type B), urethra (type A), conjunctiva (type A), skin (type A), etc. It was confirmed that it is also expressed in the tissue (Fig. 2). Tissues of type A humans can only be stained with antibodies that recognize A antigen, not with antibodies that recognize B antigen, and those with type B can only be stained with antibodies that recognize B antigen. Both types of humans were able to stain both antibodies, while those of type O were not stained.
- the ABH antigen was normally expressed up to 24 hours, but the expression of the ABH antigen gradually disappeared at 48 and 72 hours (FIG. 3).
- the A, B, and H antigens (purchased from Dextra Laboratories) were treated with HaCaT cells containing the B antigen at a concentration of 100 nM for 24 hours, and then the expression of the B antigen was observed by Western blot analysis. As a result, the expression of type B antigen was increased by the B and H antigens, respectively, and the A antigen did not increase the expression of the type B antigen at 24 hours (Fig. 7-0). In addition, when A and B antigens were treated with HaCaT cells at a concentration of 100 nM or 200 nM for 48 hours, both A and B antigens increased the expression of type B antigens (FIG. 7). From the above results, it was confirmed that all of the A, B, and H antigens increase the expression of the B-type antigen of HaCaT cells.
- the lysate was attached to the hip skin of a 30-year-old male type A atopic patient (volunteer) and a 24-year-old male type A atopic patient (volunteer) and treated twice a day for 48 hours (total 96 hours) to obtain a biopsy tissue. Biopsied tissues were examined for expression of ABH antigens in each tissue in the same manner as in immunohistochemical staining described in Experimental Example 1, using antibodies that specifically bind to ABH antigens.
- Th1 cytokine interferon gamma
- IFNg interferon gamma
- keratinocytes as antigen-providing cells.
- the most important molecules at this time are ICAM-1 and HLA-DR (Barker et al. , Lancet 337: 211-214 (1991)).
- HaCaT cells a keratinocyte cell line containing B antigen, were cultured in DMEM (Dulbecco's modificastion of Eagle's medium, Welgene) medium containing 5% FBS (Fetal bovine serum, Hyclone).
- RNA (Bioneer) having no target gene and siRNA (Bioneer, SEQ ID NO: 1) targeting the FUT1 gene were transfected with a negative control group.
- the expression of ICAM-1 and HLA-DR is greatly increased by interferon gamma.
- the interferon was suppressed. It was confirmed that the increase in expression of ICAM-1 by gamma was largely suppressed, and in the case of HLA-DR, the increase in expression until the initial 18 hours was suppressed, but recovered after 24 hours and reversed at 48 hours ( 10).
- HaCaT cells keratinocytes containing B antigens, were treated with Lipofectamine 20 million in the same manner as in Experiment 4 (CNT), RNA (NC) and FUT1 (siFUT1) without target genes as negative controls, Four types of samples transfected with 250 pmol of siRNA (Bioneer) targeting the ABO (siABO) gene were not treated with interferon gamma, or treated at a concentration of 10 ng / ml, and then cells were treated 24 hours later.
- the siRNA sequence of the FUT1 gene is the same as Experimental Example 4, the siRNA sequence of the ABO gene was used as the base sequence described in SEQ ID NO: 2.
- the primers of the human IL-8 gene was used as the nucleotide sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4, the primers of GM-CSF was used as the base sequence described in SEQ ID NO: 5 and SEQ ID NO: 6, As the primer of BD-2, the nucleotide sequences described in SEQ ID NO: 7 and SEQ ID NO: 8 were used.
- the lentiviral vector capable of overexpressing the shRNA of the FUT1 gene and the lentiviral vector capable of overexpressing the shRNA of the ABO gene were infected with HaCaT cell line, followed by selective culture with puromycin for one month.
- a HaCaT cell line was constructed in which the expression of FUT1 or ABO was stably inhibited compared to the negative control lentiviral vector.
- the expression level of mRNA of BD-2 was corrected by the expression level of 36b4 gene and compared with the same real-time RT-PCR method as in Experimental Example 7.
- SiRNA was not treated in the HaCaT cell line, or in the same manner as in Experiment 4, the siRNA of the negative control siRNA (NC), FUT1 or ABO was transfected with lipofectamine 2000 and cultured until the plate was full. , Scratched to a constant width to create a cell-free space. While culturing in DMEM medium containing 10% FBS, photographs were taken at 0, 24, 48, 72 and 96 hours, respectively, to confirm cell migration.
- NC negative control siRNA
- FUT1 or ABO was transfected with lipofectamine 2000 and cultured until the plate was full. , Scratched to a constant width to create a cell-free space. While culturing in DMEM medium containing 10% FBS, photographs were taken at 0, 24, 48, 72 and 96 hours, respectively, to confirm cell migration.
- ABH antigens As described above, the expression of ABH antigens is reduced in various inflammatory skin diseases. Forcibly removing ABH antigens from keratinocytes results in various Th1 immune response factors induced by interferon gamma. As it decreased, the immune system was found to be weaker than normal. Therefore, it was confirmed that controlling the expression of the ABH antigen has an effect of controlling the degree of the inflammatory response.
- a syrup containing 20% (weight / volume) of active ingredient was prepared by the following method. First, H-type antigen, saccharin, and sugar were dissolved in 80 g of warm water. After the solution was cooled, a solution consisting of glycerin, saccharin, spices, ethanol, sorbic acid and distilled water was prepared and mixed thereto. Water was added to this mixture to 100 ml.
- the components of the syrup are as follows.
- the components of the tablet are as follows.
- Injectable solutions containing 10 mg of the active ingredient were prepared in the following manner.
- 100 g were made by dissolving 1 g of antigen A, 0.6 g of sodium chloride and 0.1 g of ascorbic acid in distilled water. The solution was bottled and heated to sterilize.
- the components of the injection solution are as follows.
- A-type antigen ... g 1 g
- Cosmetics of emulsion formulations were prepared with the compositions shown in Table 1.
- the manufacturing method is as follows.
- step 3 While passing through the step 3), the mixture of 2) was slowly added to emulsify for 2-3 minutes at 8,000 rpm.
- step 6) 15 to 17 of the raw materials were weighed, respectively, and added to the mixture of step 5) and emulsified for 30 seconds.
- step 7) After emulsifying the mixture of step 6) through a degassing process was cooled to 25 ⁇ 35 °C to prepare an emulsion-type cosmetics.
- Emulsifying Formulation 1 Stearic acid 0.3 0.3 0.3 2 Stealy alcohol 0.2 0.2 0.2 3 Glyceryl Monostearate 1.2 1.2 1.2 4 Beeswax 0.4 0.4 0.4 5 Polyoxyethylene sorbitan monolauric acid ester 2.2 2.2 2.2 6 Methyl paraoxybenzoate 0.1 0.1 0.1 7 Paraoxybenzoic Acid Profiles 0.05 0.05 0.05 8 Cetylethylhexanoate 5 5 5 9 Triglycerides 2 2 10 Cyclomethicone 3 3 3 11 Distilled water to 100 to 100 to 100 12 Dark glycerin 5 5 5 13 Triethanolamine 0.15 0.15 0.05 14 Polyacrylic acid polymer 0.12 0.12 0.12 15 Pigment 0.0001 0.0001 0.0001 16 incense 0.10 0.10 0.10 17 Type A antigen 0.0001 One 10
- the cosmetic of the solubilized formulation was prepared with the composition shown in Table 2.
- the manufacturing method is as follows.
- Raw materials 2 to 6 were placed in raw material 1 (purified water) and dissolved using a still mixer.
- step 2) The mixture of step 2) was solubilized with slow addition to the mixture of step 1).
- Solubilized Formulation 1 Solubilized Formulation 2
- Solubilized Formulation 3 One Purified water to 100 to 100 to 100 2
- Dark glycerin 3 3 3
- 1,3-butylene glycol 2 2
- EDTA-2Na 0.01 0.01 0.01
- B-type antigen 0.1 5 5
- 8 8 8
- Methyl paraoxybenzoate 0.1 0.1 0.1 9 Polyoxyethylene Hydrogenate Diester 0.3 0.3 0.3 10 incense 0.15 0.15 0.15 11 Cyclomethicone - - 0.2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
Abstract
Description
조성 | 유화 제형 1 | 유화 제형 2 | 유화 제형 3 | |
1 | 스테라인산 | 0.3 | 0.3 | 0.3 |
2 | 스테알리 알코올 | 0.2 | 0.2 | 0.2 |
3 | 글리세릴 모노스테아레이트 | 1.2 | 1.2 | 1.2 |
4 | 밀납 | 0.4 | 0.4 | 0.4 |
5 | 폴리옥시에틸렌솔비탄모노라우린산 에스테르 | 2.2 | 2.2 | 2.2 |
6 | 파라옥시안식향산 메틸 | 0.1 | 0.1 | 0.1 |
7 | 파라옥시안식향산 프로필 | 0.05 | 0.05 | 0.05 |
8 | 세틸에틸헥사노에이트 | 5 | 5 | 5 |
9 | 트리글리세라이드 | 2 | 2 | 2 |
10 | 사이클로메티콘 | 3 | 3 | 3 |
11 | 증류수 | to 100 | to 100 | to 100 |
12 | 진한 글리세린 | 5 | 5 | 5 |
13 | 트리에탄올아민 | 0.15 | 0.15 | 0.05 |
14 | 폴리아크릴산 중합체 | 0.12 | 0.12 | 0.12 |
15 | 색소 | 0.0001 | 0.0001 | 0.0001 |
16 | 향 | 0.10 | 0.10 | 0.10 |
17 | A형 항원 | 0.0001 | 1 | 10 |
조성 | 가용화 제형 1 | 가용화 제형 2 | 가용화 제형 3 | |
1 | 정제수 | to 100 | to 100 | to 100 |
2 | 진한 글리세린 | 3 | 3 | 3 |
3 | 1,3-부틸렌글리콜 | 2 | 2 | 2 |
4 | EDTA-2Na | 0.01 | 0.01 | 0.01 |
5 | 색소 | 0.0001 | 0.0002 | 0.0002 |
6 | B형 항원 | 0.1 | 5 | 5 |
7 | 알코올(95%) | 8 | 8 | 8 |
8 | 파라옥시안식향산 메틸 | 0.1 | 0.1 | 0.1 |
9 | 폴리옥시에틸렌하이드로제네이트디 에스테르 | 0.3 | 0.3 | 0.3 |
10 | 향 | 0.15 | 0.15 | 0.15 |
11 | 사이클로메티콘 | - | - | 0.2 |
Claims (15)
- ABH 항원 또는 상기 ABH 항원의 발현을 조절하는 물질을 유효성분으로 함유하는 염증질환 개선용 조성물.
- 청구항 1에 있어서,상기 염증질환은 염증성 피부질환 및 위장, 식도, 소장, 요도 및 결막으로 구성된 군으로부터 선택되는 조직의 염증성 질환으로 구성된 군으로부터 선택되는 조성물.
- 청구항 1에 있어서,상기 ABH 항원의 발현을 조절하는 물질은 ABH 항원의 발현을 증가시키는 물질 또는 ABH 항원의 발현을 감소시키는 물질인 것을 특징으로 하는 조성물.
- 청구항 3에 있어서,상기 ABH 항원의 발현을 증가시키는 물질은 ABO, FUT1 및 FUT2로 구성된 군으로부터 선택되는 유전자 또는 상기 유전자를 포함하는 벡터인 것을 특징으로 하는 조성물.
- 청구항 3에 있어서,상기 ABH 항원의 발현을 감소시키는 물질은 ABO, FUT1 및 FUT2로 구성된 군으로부터 선택되는 유전자의 발현을 억제하는 siRNA, shRNA 및 상기 siRNA나 shRNA의 안티센스 코딩 서열을 포함하는 벡터로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 청구항 2에 있어서,상기 염증성 피부질환은 건선, 아토피, 어린선, 천포창, 여드름, 홍반성 루푸스, 피부노화 및 피부주름으로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 청구항 1에 있어서,상기 ABH 항원 또는 상기 ABH 항원의 발현을 조절하는 물질은 전체 조성물 중에 0.001 내지 10 중량%의 양으로 함유되는 것을 특징으로 하는 조성물.
- 청구항 1 내지 청구항 7 중 어느 한 항에 있어서,상기 조성물은 약학적 조성물 또는 화장료 조성물의 형태인 것을 특징으로 하는 조성물.
- 청구항 8에 있어서,상기 조성물의 제형은 피부 외용제 제형인 것을 특징으로 하는 조성물.
- 청구항 8에 있어서,상기 화장료 조성물은 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤, 피부 점착타입의 화장료 제형, 로션, 연고, 크림, 패취 및 분무제로 구성된 군으로부터 선택되는 조성물.
- 청구항 8에 있어서,상기 약학적 조성물은 고체, 반고체 및 액상으로 구성된 군으로부터 선택되는 경구 또는 비경구 투여제 형태인 것을 특징으로 하는 조성물.
- 청구항 1에 있어서,상기 ABH 항원은 단백질이나 지질의 당질화 말단의 구조가 푸코오스-갈락토오스 말단에 N-아세틸갈락토사민이 결합한 A 항원, 푸코오스-갈락토오스 말단에 갈락토오스가 결합한 B 항원, 푸코오스-갈락토오스 말단에 N-아세틸갈락토사민과 갈락토오스가 모두 결합한 AB 항원, 푸코오스-갈락토오스 말단에 아무것도 결합하지 않은 H 항원으로 구성된 군으로부터 선택되는 조성물.
- 청구항 1항 또는 청구항 11에 있어서,상기 ABH 항원은 푸코오스, 갈락토오스, 글루코오스, N-아세틸갈락토사민, N-아세틸글루코사민, FG(Fucose:Galactose = 1:1, H-antigen 조성), FGG(Fucose:Galactose = 1:2, B-antigen 조성) 및 FGGN(Fucose:Galactose:N-acetylgalactosamine = 1:1:1, A-antigen 조성)으로 구성된 군으로부터 선택되는 조성물.
- 청구항 3에 있어서,상기 ABH 항원의 발현을 증가시키는 물질은 버드나무 추출물 또는 황금 추출물인 조성물.
- 청구항 3에 있어서,상기 ABH 항원의 발현을 감소시키는 물질은 가시오가피 추출물, 엉겅퀴 추출물, 표고버섯 추출물, 인삼 추출물 및 에키나시아 추출물로 구성된 군으로부터 선택되는 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080011075.XA CN102355910B (zh) | 2009-01-09 | 2010-01-07 | 利用abh抗原改善炎症性疾病的组合物 |
EP10729320.1A EP2377558A4 (en) | 2009-01-09 | 2010-01-07 | COMPOSITION TO TREAT INFLAMMATORY DISEASES WITH ABH ANTIGENES |
JP2011545293A JP2012514634A (ja) | 2009-01-09 | 2010-01-07 | Abh抗原を利用した炎症疾患改善用組成物 |
US13/143,462 US8545851B2 (en) | 2009-01-09 | 2010-01-07 | Composition for improving inflammatory disease using ABH antigens |
US14/014,861 US20140037773A1 (en) | 2009-01-09 | 2013-08-30 | Composition for improving inflammatory disease using abh antigens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0002078 | 2009-01-09 | ||
KR20090002078 | 2009-01-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/143,462 A-371-Of-International US8545851B2 (en) | 2009-01-09 | 2010-01-07 | Composition for improving inflammatory disease using ABH antigens |
US14/014,861 Division US20140037773A1 (en) | 2009-01-09 | 2013-08-30 | Composition for improving inflammatory disease using abh antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010079978A2 true WO2010079978A2 (ko) | 2010-07-15 |
WO2010079978A3 WO2010079978A3 (ko) | 2010-11-11 |
Family
ID=42317000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/000103 WO2010079978A2 (ko) | 2009-01-09 | 2010-01-07 | Abh 항원을 이용한 염증질환 개선용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8545851B2 (ko) |
EP (1) | EP2377558A4 (ko) |
JP (1) | JP2012514634A (ko) |
KR (1) | KR101098581B1 (ko) |
CN (1) | CN102355910B (ko) |
WO (1) | WO2010079978A2 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101965590B1 (ko) | 2012-09-28 | 2019-04-04 | (주)아모레퍼시픽 | Abh 항원의 발현을 조절하는 물질을 포함하는 피부 미백용 조성물 |
KR101449129B1 (ko) * | 2012-10-05 | 2014-10-08 | (주)아모레퍼시픽 | Abh 항원의 발현을 조절하는 물질을 포함하는 조성물 |
KR102224110B1 (ko) * | 2014-10-15 | 2021-03-09 | (주)아모레퍼시픽 | Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물 |
JP6577581B2 (ja) * | 2014-10-15 | 2019-09-18 | アモーレパシフィック コーポレーションAmorepacific Corporation | Abh抗原の発現を調節する物質を含む組成物 |
KR102199884B1 (ko) * | 2014-10-15 | 2021-01-08 | (주)아모레퍼시픽 | Abh 항원의 발현을 조절하는 물질을 포함하는 피지 조절용 조성물 |
US10248689B2 (en) * | 2015-10-13 | 2019-04-02 | International Business Machines Corporation | Supplementing candidate answers |
WO2018146506A1 (en) * | 2017-02-10 | 2018-08-16 | Universitat Politècnica De València | Therapeutic derivatives |
US10427450B2 (en) * | 2017-09-21 | 2019-10-01 | Comsero, Inc. | Modularly stackable dry erase panels and system thereof |
KR102039094B1 (ko) * | 2018-08-02 | 2019-11-01 | (주)정진호이펙트 | 천연물 추출물 또는 단당류를 이용한 피부 보습 개선용 조성물 |
KR102100399B1 (ko) | 2019-02-21 | 2020-04-13 | 김석환 | 장애인 보도블럭 시스템 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59216821A (ja) * | 1983-05-23 | 1984-12-06 | Eisai Co Ltd | 気道閉塞性障害治療・予防剤 |
JPH0653672B2 (ja) * | 1987-12-23 | 1994-07-20 | プソリツル・リミテッド | 乾癬に対する治療用組成物 |
DE3927723A1 (de) * | 1989-01-26 | 1990-08-02 | Ulrich Prof Dr Speck | N - acetylglucosamin zur buccalen anwendung |
US5211937A (en) * | 1990-07-30 | 1993-05-18 | Glycomed Incorporated | Method of determining a site of inflammation utilizing elam-1 ligands |
US5229374A (en) * | 1992-01-28 | 1993-07-20 | Burton Albert F | Method for treatment of lower gastrointestinal tract disorders |
JP3517274B2 (ja) * | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
US5639734A (en) * | 1994-12-20 | 1997-06-17 | Esko; Jeffrey D. | Disaccharide inflammation inhibitors and uses thereof |
US5631245A (en) * | 1995-06-06 | 1997-05-20 | Biodynamics Pharmaceuticals, Inc. | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions |
AU2610097A (en) * | 1996-04-10 | 1997-10-29 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
DE19615578A1 (de) * | 1996-04-19 | 1997-10-23 | Beiersdorf Ag | Verwendung von Salix nigra-Extrakt als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen |
CA2258781A1 (en) * | 1996-06-27 | 1997-12-31 | Chune Sang | Cosmetic compositions |
AUPO182396A0 (en) * | 1996-08-23 | 1996-09-12 | Austin Research Institute, The | Improved nucleic acids for reducing carbohydrate epitopes |
FR2756735B1 (fr) * | 1996-12-11 | 1999-02-26 | Thorel Jean Noel | Agent d'inhibition de l'expression de la proteine d'adherence icam-1 et compositions cosmetiques et pharmaceutiques le contenant |
CA2234936C (en) * | 1998-04-17 | 2004-06-29 | Glucogenics Pharmaceuticals Inc. | Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
FR2811228B1 (fr) * | 2000-07-07 | 2002-10-25 | Lvmh Rech | Utilisation d'oligosaccharides ou d'extraits de plantes en contenant comme agent cosmetique ou dermatologique notamment pour stimuler la production de beta-endorphine dans la peau |
JP2002173438A (ja) * | 2000-12-05 | 2002-06-21 | Api Co Ltd | エキナセア抽出物及びその製造方法 |
FR2825632B1 (fr) * | 2001-06-11 | 2003-10-03 | Silab Sa | Procede d'extraction d'un principe actif a partir de salix, principe actif obtenu et traitements cosmetiques |
JP4421894B2 (ja) * | 2001-07-20 | 2010-02-24 | アブソーバー アクチボラゲット | 血液型抗原融合ポリペプチドおよびその使用方法 |
JP4477285B2 (ja) * | 2002-03-06 | 2010-06-09 | ピアス株式会社 | 抗炎症剤、PGE2産生抑制剤、IL−1α産生抑制剤及びIL−6産生抑制剤 |
JP2003267887A (ja) * | 2002-03-15 | 2003-09-25 | Shiseido Co Ltd | ケモカイン発現抑制皮膚外用剤 |
JP3886116B2 (ja) * | 2002-05-16 | 2007-02-28 | 株式会社ノエビア | 皮膚外用剤 |
DE10239029A1 (de) * | 2002-08-21 | 2004-03-04 | Coty B.V. | Kosmetische und dermatologische Zubereitung mit Proteinen zur Hautaufhellung |
WO2005000860A2 (en) * | 2003-06-03 | 2005-01-06 | The Regents Of The University Of California | Compositions and methods for treatment of disease with acetylated disaccharides |
KR100431076B1 (ko) * | 2003-06-16 | 2004-05-12 | 주식회사 코스메카코리아 | 천연 혼합 추출물을 함유하는 아토피 피부의 치유개선효과를 갖는 화장료 |
US20050031710A1 (en) * | 2003-08-08 | 2005-02-10 | D'adamo Peter James | Method of personal care and cosmetic product preparation and composition using human blood type |
CA2540586A1 (en) * | 2003-10-01 | 2005-04-21 | Optimer Pharmaceuticals, Inc. | Treatment of a condition in a mammal with administration of aminosugar and uses thereof |
MX2007000613A (es) * | 2004-07-16 | 2007-06-25 | Johnson & Johnson | Tratamiento de la piel con luz y un agente de beneficio. |
WO2006055711A1 (en) * | 2004-11-18 | 2006-05-26 | Kent Hann | Compositions containing aloe vera isolate and a prebiotic and their therapeutic application |
KR20060077744A (ko) * | 2004-12-30 | 2006-07-05 | 백연진 | 항문질환과 음부질환 및 피부질환 치료용 생약조성물 |
US20060177527A1 (en) * | 2005-02-04 | 2006-08-10 | Shoshana Moses | Methods and compositions for treating psoriasis |
JP2006321758A (ja) * | 2005-05-19 | 2006-11-30 | System Kyokai:Kk | 化粧品 |
JP2006347911A (ja) * | 2005-06-14 | 2006-12-28 | Ogawa & Co Ltd | 保湿性植物抽出物並びに該抽出物を含有する外用剤、化粧料、浴用剤及び洗剤 |
JP5139629B2 (ja) * | 2005-06-28 | 2013-02-06 | 江崎グリコ株式会社 | TNF−αおよび一酸化窒素産生抑制剤 |
EP1940433B1 (en) * | 2005-10-01 | 2013-09-04 | ELC Management LLC | Compositions comprising hypsizygus ulmarius extract |
US8435588B2 (en) | 2005-11-23 | 2013-05-07 | The Coca-Cola Company | High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith |
KR20070091746A (ko) * | 2006-03-07 | 2007-09-12 | 주식회사 엘지생활건강 | 가시오가피 추출물로 된 항산화제 및 이를 함유하는건강기능식품 |
JP5044166B2 (ja) * | 2006-08-16 | 2012-10-10 | 株式会社レドックス | エゾウコギの茎及び/又は枝の抽出物の製造方法 |
FR2906722B3 (fr) * | 2006-10-10 | 2009-04-17 | Sephar Sarl | Nouvelle composition pharmaceutique et cosmetique et ses applications dermatologiques dans les corrections des epitheliums deshydrates |
KR20080104600A (ko) * | 2007-05-28 | 2008-12-03 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및허혈성 심질환 치료용 조성물 |
JP5398129B2 (ja) * | 2007-07-02 | 2014-01-29 | 小林製薬株式会社 | 肌新陳代謝促進剤 |
US7666450B2 (en) * | 2007-12-04 | 2010-02-23 | Apptec, Inc. | Herbal compositions for the regression of chronic inflammatory skin disorders |
US7785638B2 (en) * | 2008-02-28 | 2010-08-31 | Himalaya Global Holdings, Ltd | Herbal acne control composition, method of manufacturing the same and use thereof |
-
2009
- 2009-12-03 KR KR1020090119140A patent/KR101098581B1/ko active IP Right Grant
-
2010
- 2010-01-07 CN CN201080011075.XA patent/CN102355910B/zh active Active
- 2010-01-07 WO PCT/KR2010/000103 patent/WO2010079978A2/ko active Application Filing
- 2010-01-07 US US13/143,462 patent/US8545851B2/en active Active
- 2010-01-07 EP EP10729320.1A patent/EP2377558A4/en not_active Withdrawn
- 2010-01-07 JP JP2011545293A patent/JP2012514634A/ja active Pending
-
2013
- 2013-08-30 US US14/014,861 patent/US20140037773A1/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
BARKER ET AL., LANCET, vol. 337, 1991, pages 211 - 214 |
DABELSTEEN ET AL., J INVEST DERMATOL, vol. 82, 1984, pages 13 - 17 |
GREENWELL, GLYCOCONJUGATE J, vol. 14, 1997, pages 159 - 173 |
LLOYD, GLYCOCONJIIGATE J, vol. 17, 2000, pages 531 - 541 |
RAVN ET AL., APMIS, vol. 108, 2000, pages 1 - 28 |
See also references of EP2377558A4 |
Also Published As
Publication number | Publication date |
---|---|
CN102355910B (zh) | 2016-02-10 |
KR101098581B1 (ko) | 2011-12-26 |
US8545851B2 (en) | 2013-10-01 |
US20140037773A1 (en) | 2014-02-06 |
EP2377558A4 (en) | 2013-11-20 |
WO2010079978A3 (ko) | 2010-11-11 |
EP2377558A2 (en) | 2011-10-19 |
JP2012514634A (ja) | 2012-06-28 |
KR20100082709A (ko) | 2010-07-19 |
US20110274707A1 (en) | 2011-11-10 |
CN102355910A (zh) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010079978A2 (ko) | Abh 항원을 이용한 염증질환 개선용 조성물 | |
WO2022145663A1 (ko) | 락토바실러스 플란타룸 유산균 사균체 또는 상기 유산균의 배양물을 포함하는 피부 노화 방지 또는 개선용 화장료 조성물 | |
WO2016167527A1 (ko) | 백미 추출물의 지표성분인 시나프산 또는 이를 함유하는 백미 추출물을 함유하는 피부재생용 화장료 조성물 및 상처 치료용 약학 조성물 | |
WO2019004757A9 (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 가려움증 억제 또는 개선 용도 | |
WO2020218846A1 (ko) | 우유 엑소좀을 포함하는 피부 미백용 조성물 | |
WO2012002730A2 (ko) | 봉독 추출물을 함유하는 피부 미백 및 보습용 조성물 | |
WO2014077568A1 (ko) | 티오레독신을 함유하는 피부 외용제 조성물 | |
WO2017061769A1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 탈모방지 또는 발모촉진용 조성물 | |
WO2017217695A1 (ko) | 알파-망고스틴, 베타-망고스틴, 감마-망고스틴 또는 가르탄닌 화합물을 유효성분으로 함유하는 피부 주름 개선 또는 피부 보습용 조성물 | |
WO2019004738A2 (ko) | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 | |
WO2023054817A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2014175676A1 (ko) | 진세노사이드 rf를 함유하는 피부 외용제 조성물 | |
WO2021096089A1 (ko) | 줄기세포 유래 엑소좀과 폴리데옥시리보뉴클레오티드를 유효성분으로 포함하는 새로운 조성물 | |
WO2021095966A1 (ko) | 클로렐라 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물 | |
WO2019190010A1 (ko) | 피부 주름 개선, 보습, 항산화 및 염증 완화 효과가 증가된 진피, 후박, 현호색, 아선약의 에탄올 추출 조성물 | |
WO2019151585A1 (ko) | 5-아이오도튜베르시딘을 유효성분으로 함유하는 피부미백용 조성물 | |
WO2018194261A1 (ko) | 4'-o-메틸알피눔 이소플라본의 치료적 용도 | |
WO2018151563A1 (ko) | 코스모스 추출물을 포함하는 광노화 방지 및 피부주름 개선용 조성물 | |
WO2011136561A2 (ko) | 세로토닌을 유효성분으로 포함하는 백반증 치료용 조성물 | |
WO2024049226A1 (ko) | 남가새 유래 화합물을 유효성분으로 포함하는 피부 질환 예방 또는 개선용 화장료 조성물 | |
WO2024049229A1 (ko) | 뽕나무 유래 화합물을 유효성분으로 포함하는 피부 질환 예방 또는 개선용 화장료 조성물 | |
WO2017171404A1 (ko) | 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물 | |
WO2023090781A1 (ko) | 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물 | |
WO2023018316A1 (ko) | 개선된 세포 투과성 핵 수송 억제제를 포함하는 피부 노화 방지 또는 피부 주름 개선용 화장료 조성물 | |
WO2024090922A1 (ko) | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080011075.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10729320 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13143462 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2010729320 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010729320 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011545293 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |